Soleno Therapeutics (SLNO) Cash & Equivalents: 2013-2019
Historic Cash & Equivalents for Soleno Therapeutics (SLNO) over the last 6 years, with Sep 2019 value amounting to $11.2 million.
- Soleno Therapeutics' Cash & Equivalents rose 9.63% to $11.2 million in Q3 2019 from the same period last year, while for Sep 2019 it was $11.2 million, marking a year-over-year increase of 9.63%. This contributed to the annual value of $23.1 million for FY2018, which is 35.08% up from last year.
- Per Soleno Therapeutics' latest filing, its Cash & Equivalents stood at $11.2 million for Q3 2019, which was down 27.59% from $15.5 million recorded in Q2 2019.
- Over the past 5 years, Soleno Therapeutics' Cash & Equivalents peaked at $23.1 million during Q4 2018, and registered a low of $2.5 million during Q2 2016.
- Moreover, its 3-year median value for Cash & Equivalents was $12.6 million (2018), whereas its average is $13.4 million.
- Per our database at Business Quant, Soleno Therapeutics' Cash & Equivalents soared by 7,275.00% in 2015 and then tumbled by 66.77% in 2016.
- Over the past 5 years, Soleno Therapeutics' Cash & Equivalents (Quarterly) stood at $5.5 million in 2015, then plummeted by 50.39% to $2.7 million in 2016, then skyrocketed by 527.29% to $17.1 million in 2017, then surged by 35.08% to $23.1 million in 2018, then climbed by 9.63% to $11.2 million in 2019.
- Its Cash & Equivalents was $11.2 million in Q3 2019, compared to $15.5 million in Q2 2019 and $19.4 million in Q1 2019.